Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$302.41 USD

302.41
540,914

-2.40 (-0.79%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $302.41 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks News

Zacks Equity Research

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Zacks Equity Research

UTHR vs. STVN: Which Stock Is the Better Value Option?

UTHR vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Zacks Equity Research

Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study

MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Zacks Equity Research

United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

United Therapeutics Q3 Earnings & Sales Beat Estimates

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

Zacks Equity Research

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 3.40% and 4.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Zacks Equity Research

Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for United Therapeutics (UTHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.